News

AbstractWild-type transthyretin cardiac amyloidosis (ATTRwt) is an underrecognized cause of heart failure that often mimics hypertensive or nonischemic…

AbstractTransthyretin amyloidosis (ATTR) is a rare, progressive, and fre- quently under-recognized systemic disease whose early clinical manifes- tations may…

Prothena Biosciences announced that coramitug (previously PRX004) has received Fast Track designation for the treatment of transthyretin amyloid cardiomyopathy…

Older patients hospitalized due to heart failure in the US were cared for with frequent outpatient clinic visits before and after heart failure hospitalization,…

TOPLINE:In patients newly diagnosed with cardiac amyloidosis (CA), continuous rhythm monitoring using implantable loop recorders found that clinically significant…

Cardiovascular diseases could be among the world’s first medical conditions to be treated by changing a patient’s genes. If ongoing phase 3 trials succeed, gene…

AbstractBackground and Purpose: Transthyretin (ATTR) amyloidosis, including wild-type (ATTRwt) and hereditary (ATTRv) forms, is a rare but increasingly recognized…

Introduction. Heart failure (HF) is a leading cause of hospitalization in Internal Medicine and HF with preserved ejection fraction (HFpEF) accounts for…

TARRYTOWN, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2…

join us for an informative, patient-centered webinar featuring cardiology and hematology experts, along with two patients sharing their lived experiences with…